Table 2.
Clinical characteristics at baseline
| Clinical baseline data | Prostatectomy (%) | Radiotherapy (%) | Total (%) |
|---|---|---|---|
| Number of patients | 301 (100) | 299 (100) | 600 (100) |
| Previous active surveillance | |||
| Yes | 15 (5) | 15 (5) | 30 (5) |
| No | 268 (89) | 263 (88) | 531 (88) |
| Missing | 18 (6) | 21 (7) | 39 (7) |
| PSA at inclusion (µg/l) | |||
| Median | 13.0 | 11.0 | 12.0 |
| Interquartile range (25p–75p) | 7.5–26.0 | 7.3–23.0 | 7.5–24.8 |
| % PSA >20 | 34 | 28 | 31 |
| Missing | 0 (0) | 0 (0) | 0 (0) |
| Clinical T stage (DRE) | |||
| T1 | 19 (6) | 20 (7) | 39 (7) |
| T2 | 33 (11) | 34 (11) | 67 (11) |
| T3 | 248 (82) | 244 (82) | 492 (82) |
| T4 | 1 (0) | 0 (0) | 1 (0) |
| Missing | 0 (0) | 1 (0) | 0 (0) |
| Imaging T stage (MRI) | |||
| No. of patients undergoing MRI | 179 | 182 | 361 |
| T1 | 3 (2a) | 1 (1a) | 4 (1a) |
| T2 | 6 (3) a | 4 (2a) | 10 (3a) |
| T3 | 163 (91a) | 167 (92a) | 330 (91a) |
| T4 | 7 (4a) | 10 (5a) | 17 (5a) |
| Missing | 0 (0a) | 0 (0a) | 0 (0a) |
| Prostate volume (cc) | |||
| Median | 38.5 | 36.0 | 37.0 |
| IQ range (25p–75p) | 30.0–50.5 | 30.0–45.0 | 30.0–48.9 |
| % >50 cc | 25 | 16 | 20,0 |
| Missing | 17 (6) | 20 (7) | 37 (6) |
| ISUP grade | |||
| Grade group 1 | 0 (0) | 0 (0) | 0 (0) |
| Grade group 2 | 78 (26) | 76 (25) | 154 (26) |
| Grade group 3 | 87 (29) | 80 (27) | 168 (28) |
| Grade group 4 | 49 (16) | 62 (21) | 111 (19) |
| Grade group 5 | 87 (29) | 79 (26) | 166 (28) |
| Missing | 0 (0) | 2 (1) | 2 (0) |
| Biopsies | |||
| No of coresb | |||
| 2–5 | 17 (6) | 27 (9) | 44 (7) |
| 6–9 | 29 (10) | 27 (9) | 56 (9) |
| 10–14 | 238 (79) | 235 (79) | 473 (79) |
| ≥15 | 6 (2) | 2 (1) | 8 (1) |
| Missing | 11 (4) | 8 (3) | 19 (3) |
| Total biopsy length (mm) | |||
| <50 | 17 (6) | 30 (10) | 47 (8) |
| 50–99 | 29 (10) | 32 (11) | 61 (10) |
| 100–199 | 208 (69) | 189 (63) | 397 (66) |
| ≥200 | 20 (7) | 26 (9) | 46 (8) |
| Missing | 27 (9) | 22 (7) | 49 (8) |
| Number of cores with cancer | |||
| 1–4 biopsies | 60 (20) | 82 (27) | 142 (24) |
| 5–9 biopsies | 147 (49) | 144 (48) | 291 (49) |
| ≥10 biopsies | 81 (27) | 63 (21) | 144 (24) |
| Missing | 13 (4) | 10 (3) | 23 (4) |
| Total cancer length (mm) | |||
| <20 | 44 (15) | 53 (18) | 97 (16) |
| 20–49 | 101 (34) | 105 (35) | 206 (34) |
| 50–99 | 103 (34) | 93 (31) | 196 (33) |
| 100–149 | 29 (10) | 28 (9) | 57 (10) |
| >150 | 7 (2) | 6 (2) | 13 (2) |
| Missing | 17 (6) | 14 (5) | 31 (5) |
| Charlson comorbidity indexc | |||
| 0–2 | 29 (10) | 33 (11) | 62 (10) |
| 3–4 | 228 (76) | 220 (74) | 448 (75) |
| >4 | 29 (10) | 33 (11) | 28 (5) |
| Missing | 15 (5) | 13 (4) | 28 (5) |
CCI = Charlson comorbidity index; DRE = digital rectal examination; IQ = interquartile; ISUP = International Society of Urological Pathology; MRI = magnetic resonance imaging; PSA = prostate-specific antigen.
a
% out of patients undergoing MRI.
b
Low number of biopsies mainly due to fusion or targeted biopsies.
c
No points for prostate cancer in CCI tumor.